Gemtuzumab ozogamicin (Mylotarg®) which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||21/06/2018|
|Rapid review completed||17/07/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||31/07/2018|